Tenofovir Alafenamide May Offer Safety Benefit over Tenofovir Disoproxil Fumarate

Results from a phase II study suggest that TAF may have less renal and bone toxicity than TDF when combined with elvitegravir/cobicistat/FTC.

Because of its safety and efficacy, tenofovir disoproxil fumarate (TDF) is an important component of many key antiretroviral therapy regimens, despite concerns about renal and bone toxicity with long-term use. Tenofovir alafenamide (TAF) addresses some of those concerns, in part because the plasma levels needed to maintain antiviral efficacy are lower.

In a recent manufacturer-funded, phase II, double-blind study, researchers compared the safety and efficacy of single-tablet regimens containing elvitegravir/cobicistat/FTC plus either TAF (25 mg) or TDF (300 mg). Study participants — 170 HIV-infected, treatment-naive adults — were randomized 2:1 to the TAF or TDF formulation.

At 48 weeks, 88% of each study arm had viral loads <50 copies/mL. TA…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Tenofovir Alafenamide May Offer Safety Benefit over Tenofovir Disoproxil Fumarate

Topics

Reviewing Author